Compare AstraZeneca plc (AZN) vs JPMorgan Diversified Return International Eqty ETF (JPIN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs JPMorgan Diversified Return International Eqty ETF — how do they compare? AstraZeneca plc trades at $158.41 (market cap $248.14B), while JPMorgan Diversified Return International Eqty ETF trades at $77. The key difference: AstraZeneca plc pays a 2.01% dividend while JPMorgan Diversified Return International Eqty ETF pays none, and JPMorgan Diversified Return International Eqty ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | JPIN | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | — |
52-Week High | $209.48 | $77.00 |
52-Week Low | $147.06 | $64.96 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
JPIN trades at $76.515, up 0.2% today, with technical indicators signaling a bullish trend from moving averages but caution from overbought RSI levels. The ETF, launched in 2014, provides exposure to foreign large-cap value stocks, with a dividend scheduled for June 2026. Recent news highlights its smart beta strategy and broad market category focus.
The outlook remains positive due to strong technical momentum and diversified international equity exposure, though overbought conditions and reliance on global markets pose risks. Investors benefit from value-oriented strategies but should monitor international economic volatility for potential impacts on performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About JPMorgan Diversified Return International Eqty ETF
The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.
Read more on JPIN →
